

Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Growth 2024-2030

<https://marketpublishers.com/r/G7B790FE0BBFEN.html>

Date: November 2024

Pages: 113

Price: US\$ 3,660.00 (Single User License)

ID: G7B790FE0BBFEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Hereditary Transthyretin Amyloid Neuropathy(ATTRv-PN)is a progressive and debilitating condition caused by the deposition of abnormal transthyretin protein in peripheral nerves.Current therapeutic approaches include stabilizers of transthyretin tetramers such as tafamidis.Other options involve gene silencing therapies like RNA interference(RNAi)with drugs such as patisiran and inotersen,which reduce the production of abnormal transthyretin protein in the liver.

The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Forecast” looks at past sales and reviews total world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales in 2023, providing a comprehensive analysis by region and market sector of projected Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales for 2024 through 2030. With Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) industry.

This Insight Report provides a comprehensive analysis of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share,

latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).

United States market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) players cover Alnylam Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Pfizer, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Transthyretin Tetramer Stabilizer

RNA Interference

Antisense Oligonucleotides

Other

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Alnylam Pharmaceuticals

Akcea Therapeutics

AstraZeneca

Pfizer

Teva

Zydus Pharms

Avet Pharmaceuticals

Luoxin Pharmaceutical

Zhengzhou Taifeng Pharmaceutical

Shapuaisi Pharma

Tonghua Zhongsheng Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?

What factors are driving Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market opportunities vary by end market size?

How does Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Annual Sales 2019-2030

2.1.2 World Current & Future Analysis for Treatment of Hereditary Transthyretin
Amyloid Neuropathy (ATTRv-PN) by Geographic Region, 2019, 2023 & 2030

2.1.3 World Current & Future Analysis for Treatment of Hereditary Transthyretin
Amyloid Neuropathy (ATTRv-PN) by Country/Region, 2019, 2023 & 2030

2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment
by Type

2.2.1 Transthyretin Tetramer Stabilizer

2.2.2 RNA Interference

2.2.3 Antisense Oligonucleotides

2.2.4 Other

2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by
Type

2.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Sales Market Share by Type (2019-2024)

2.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Revenue and Market Share by Type (2019-2024)

2.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Sale Price by Type (2019-2024)

2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment
by Application

2.4.1 Hospital and Clinic

2.4.2 Retail Pharmacies

2.4.3 Other

2.5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application

2.5.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)

2.5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue and Market Share by Application (2019-2024)

2.5.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Breakdown Data by Company

3.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Company (2019-2024)

3.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)

3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Company (2019-2024)

3.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024)

3.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2019-2024)

3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Company

3.4 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Location Distribution

3.4.2 Players Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION

4.1 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Geographic Region (2019-2024)

4.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country/Region (2019-2024)

4.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Country/Region (2019-2024)

4.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Country/Region (2019-2024)

4.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth

4.4 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth

4.5 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth

4.6 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth

5 AMERICAS

5.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country

5.1.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)

5.1.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)

5.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)

5.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Region

6.1.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Region (2019-2024)

6.1.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Revenue by Region (2019-2024)

6.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Type (2019-2024)

6.3 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country

7.1.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Country (2019-2024)

7.1.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Revenue by Country (2019-2024)

7.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Type (2019-2024)

7.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country

8.1.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)

8.1.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)

8.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)

8.3 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

10.3 Manufacturing Process Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

10.4 Industry Chain Structure of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Distributors
- 11.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customer

12 WORLD FORECAST REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION

- 12.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Market Size Forecast by Region
 - 12.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Forecast by Region (2025-2030)
 - 12.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)
- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Forecast by Type (2025-2030)
- 12.7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

- 13.1 Alnylam Pharmaceuticals
 - 13.1.1 Alnylam Pharmaceuticals Company Information
 - 13.1.2 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
 - 13.1.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.1.4 Alnylam Pharmaceuticals Main Business Overview
 - 13.1.5 Alnylam Pharmaceuticals Latest Developments
- 13.2 Akcea Therapeutics
 - 13.2.1 Akcea Therapeutics Company Information
 - 13.2.2 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.2.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Akcea Therapeutics Main Business Overview

13.2.5 Akcea Therapeutics Latest Developments

13.3 AstraZeneca

13.3.1 AstraZeneca Company Information

13.3.2 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.3.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 AstraZeneca Main Business Overview

13.3.5 AstraZeneca Latest Developments

13.4 Pfizer

13.4.1 Pfizer Company Information

13.4.2 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.4.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.4.4 Pfizer Main Business Overview

13.4.5 Pfizer Latest Developments

13.5 Teva

13.5.1 Teva Company Information

13.5.2 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.5.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Teva Main Business Overview

13.5.5 Teva Latest Developments

13.6 Zydus Pharms

13.6.1 Zydus Pharms Company Information

13.6.2 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.6.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Zydus Pharms Main Business Overview

13.6.5 Zydus Pharms Latest Developments

13.7 Avet Pharmaceuticals

13.7.1 Avet Pharmaceuticals Company Information

13.7.2 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid

Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.7.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid

Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Avet Pharmaceuticals Main Business Overview

13.7.5 Avet Pharmaceuticals Latest Developments

13.8 Luoxin Pharmaceutical

13.8.1 Luoxin Pharmaceutical Company Information

13.8.2 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid

Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.8.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid

Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Luoxin Pharmaceutical Main Business Overview

13.8.5 Luoxin Pharmaceutical Latest Developments

13.9 Zhengzhou Taifeng Pharmaceutical

13.9.1 Zhengzhou Taifeng Pharmaceutical Company Information

13.9.2 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin

Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.9.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin

Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Zhengzhou Taifeng Pharmaceutical Main Business Overview

13.9.5 Zhengzhou Taifeng Pharmaceutical Latest Developments

13.10 Shapuaisi Pharma

13.10.1 Shapuaisi Pharma Company Information

13.10.2 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.10.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Shapuaisi Pharma Main Business Overview

13.10.5 Shapuaisi Pharma Latest Developments

13.11 Tonghua Zhongsheng Pharmaceutical

13.11.1 Tonghua Zhongsheng Pharmaceutical Company Information

13.11.2 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

13.11.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 Tonghua Zhongsheng Pharmaceutical Main Business Overview

13.11.5 Tonghua Zhongsheng Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

- Table 1. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Transthyretin Tetramer Stabilizer
- Table 4. Major Players of RNA Interference
- Table 5. Major Players of Antisense Oligonucleotides
- Table 6. Major Players of Other
- Table 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024) & (K Units)
- Table 8. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2019-2024)
- Table 9. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Type (2019-2024) & (\$ million)
- Table 10. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Type (2019-2024)
- Table 11. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Type (2019-2024) & (US\$/Unit)
- Table 12. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale by Application (2019-2024) & (K Units)
- Table 13. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)
- Table 14. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2019-2024) & (\$ million)
- Table 15. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2019-2024)
- Table 16. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024) & (US\$/Unit)
- Table 17. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company (2019-2024) & (K Units)
- Table 18. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)
- Table 19. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024) & (\$ millions)
- Table 20. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Revenue Market Share by Company (2019-2024)

Table 21. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sale Price by Company (2019-2024) & (US\$/Unit)

Table 22. Key ManufacturersTreatment of HereditaryTransthyretin Amyloid Neuropathy
(ATTRv-PN) Producing Area Distribution and Sales Area

Table 23. PlayersTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Products Offered

Table 24. Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sales by Geographic Region (2019-2024) & (K Units)

Table 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sales Market Share Geographic Region (2019-2024)

Table 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Revenue Market Share by Geographic Region (2019-2024)

Table 31. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sales by Country/Region (2019-2024) & (K Units)

Table 32. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sales Market Share by Country/Region (2019-2024)

Table 33. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Revenue by Country/Region (2019-2024) & (\$ millions)

Table 34. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Revenue Market Share by Country/Region (2019-2024)

Table 35. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Sales by Country (2019-2024) & (K Units)

Table 36. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Sales Market Share by Country (2019-2024)

Table 37. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Revenue by Country (2019-2024) & (\$ millions)

Table 38. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Sales byType (2019-2024) & (K Units)

Table 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-
PN) Sales by Application (2019-2024) & (K Units)

Table 40. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Sales by Region (2019-2024) & (K Units)

Table 41. APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2019-2024)

Table 42. APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2019-2024) & (\$ millions)

Table 43. APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024) & (K Units)

Table 44. APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)

Table 45. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)

Table 46. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024) & (\$ millions)

Table 47. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024) & (K Units)

Table 48. Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)

Table 49. Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)

Table 50. Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)

Table 51. Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024) & (K Units)

Table 52. Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Table 54. Key Market Challenges & Risks of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Table 55. Key Industry Trends of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Table 56. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List

Table 59. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customer List

Table 60. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Forecast by Region (2025-2030) & (K Units)

Table 61. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Region (2025-2030) & (\$ millions)

Table 62. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)

Table 63. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Country (2025-2030) & (\$ millions)

Table 64. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Region (2025-2030) & (K Units)

Table 65. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Region (2025-2030) & (\$ millions)

Table 66. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)

Table 67. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & (\$ millions)

Table 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)

Table 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & (\$ millions)

Table 70. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast byType (2025-2030) & (K Units)

Table 71. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast byType (2025-2030) & (\$ millions)

Table 72. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Application (2025-2030) & (K Units)

Table 73. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Application (2025-2030) & (\$ millions)

Table 74. Alnylam Pharmaceuticals Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 75. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 76. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 77. Alnylam Pharmaceuticals Main Business

Table 78. Alnylam Pharmaceuticals Latest Developments

Table 79. AkceaTherapeutics Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 80. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy

(ATTRv-PN) Product Portfolios and Specifications

Table 81. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 82. AkceaTherapeutics Main Business

Table 83. AkceaTherapeutics Latest Developments

Table 84. AstraZeneca Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 85. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 86. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 87. AstraZeneca Main Business

Table 88. AstraZeneca Latest Developments

Table 89. Pfizer Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 90. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 91. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 92. Pfizer Main Business

Table 93. Pfizer Latest Developments

Table 94.Teva Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 95.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 96.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 97.Teva Main Business

Table 98.Teva Latest Developments

Table 99. Zydus Pharms Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 100. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 101. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 102. Zydus Pharms Main Business

Table 103. Zydus Pharms Latest Developments

Table 104. Avet Pharmaceuticals Basic Information, Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 105. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 106. Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 107. Avet Pharmaceuticals Main Business

Table 108. Avet Pharmaceuticals Latest Developments

Table 109. Luoxin Pharmaceutical Basic Information, Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 110. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 111. Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 112. Luoxin Pharmaceutical Main Business

Table 113. Luoxin Pharmaceutical Latest Developments

Table 114. Zhengzhou Taifeng Pharmaceutical Basic Information, Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 115. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 116. Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 117. Zhengzhou Taifeng Pharmaceutical Main Business

Table 118. Zhengzhou Taifeng Pharmaceutical Latest Developments

Table 119. Shapuaisi Pharma Basic Information, Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 120. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 121. Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 122. Shapuaisi Pharma Main Business

Table 123. Shapuaisi Pharma Latest Developments

Table 124. Tonghua Zhongsheng Pharmaceutical Basic Information, Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors

Table 125. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications

Table 126. Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 127. Tonghua Zhongsheng Pharmaceutical Main Business

Table 128. Tonghua Zhongsheng Pharmaceutical Latest Developments

LIST OFFIGURES

Figure 1. Picture of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Figure 2. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate 2019-2030 (K Units)

Figure 7. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2023)

Figure 10. Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Transthyretin Tetramer Stabilizer

Figure 12. Product Picture of RNA Interference

Figure 13. Product Picture of Antisense Oligonucleotides

Figure 14. Product Picture of Other

Figure 15. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type in 2023

Figure 16. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share byType (2019-2024)

Figure 17.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Hospital and Clinic

Figure 18. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Hospital and Clinic (2019-2024) & (K Units)

Figure 19.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Retail Pharmacies

Figure 20. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Retail Pharmacies (2019-2024) & (K Units)

Figure 21.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Other

Figure 22. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Other (2019-2024) & (K Units)

Figure 23. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2023)

Figure 24. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application in 2023

Figure 25.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company in 2023 (K Units)

Figure 26. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company in 2023

Figure 27.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company in 2023 (\$ millions)

Figure 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company in 2023

Figure 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Geographic Region (2019-2024)

Figure 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Geographic Region in 2023

Figure 31. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)

Figure 32. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 (\$ millions)

Figure 33. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)

Figure 34. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 (\$ millions)

Figure 35. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-

PN) Sales 2019-2024 (K Units)

Figure 36. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 (\$ millions)

Figure 37. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)

Figure 38. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 (\$ millions)

Figure 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023

Figure 40. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)

Figure 41. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)

Figure 42. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)

Figure 43. United StatesTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 44. CanadaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 45. MexicoTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 46. BrazilTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 47. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region in 2023

Figure 48. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2019-2024)

Figure 49. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)

Figure 50. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)

Figure 51. ChinaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 52. JapanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 53. South KoreaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 54. Southeast AsiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 55. IndiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 56. AustraliaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 57. ChinaTaiwanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 58. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023

Figure 59. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)

Figure 60. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)

Figure 61. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)

Figure 62. GermanyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 63.FranceTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 64. UKTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 65. ItalyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 66. RussiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 67. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2019-2024)

Figure 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)

Figure 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)

Figure 70. EgyptTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 71. South AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 72. IsraelTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 73.TurkeyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 74. GCC CountriesTreatment of HereditaryTransthyretin Amyloid Neuropathy

(ATTRv-PN) Revenue Growth 2019-2024 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) in 2023

Figure 76. Manufacturing Process Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Figure 77. Industry Chain Structure of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)

Figure 78. Channels of Distribution

Figure 79. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Forecast by Region (2025-2030)

Figure 80. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share Forecast by Region (2025-2030)

Figure 81. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Type (2025-2030)

Figure 82. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share Forecast by Type (2025-2030)

Figure 83. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Forecast by Application (2025-2030)

Figure 84. Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G7B790FE0BBFEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7B790FE0BBFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

